[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337268-105":59,"doc-detail-337268-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","loss-of-histone-deubiquitinase-bap1-triggers-anti-tumor-immunity-research-article-summary","Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity - Research article summary","","Purpose: PD-L1 blockade immunotherapy benefits only a limited fraction of patients, and resistance is widespread, motivating a mechanistic understanding of cancer immune evasion and therapy resistance. Methods: A genome-scale CRISPR-Cas9 screen identified Bap1 as a regulator of PD-L1 expression; tumor growth and survival were assessed in syngeneic and immunocompromised mouse models using flow cytometry, RNA-seq, and CUT&Tag-seq. Results: Bap1 loss activates a cDC1-CD8+ T cell-dependent antitumor response, reshaping the microenvironment toward inflammation. Conclusion: Bap1 may serve as a biomarker for tumor stratification and a therapeutic target for cancer immunotherapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/loss-of-histone-deubiquitinase-bap1-triggers-anti-tumor-immunity-research-article-summary/337268/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/loss-of-histone-deubiquitinase-bap1-triggers-anti-tumor-immunity-research-article-summary/337268.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is PD-L1 blockade immunotherapy limited in many cancer patients?","Question",{"text":112,"@type":113},"PD-L1 blockade shows durable responses only in a small subset of patients, and resistance is common. The work emphasizes that immune evasion mechanisms regulating PD-L1 and mechanisms independent of PD-L1 contribute to low response rates.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was Bap1 identified as relevant to PD-L1 regulation?",{"text":117,"@type":113},"A genome-scale CRISPR-Cas9 screen was used to identify Bap1 as a regulator of PD-L1 expression.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune effects result from loss of Bap1 in tumors?",{"text":121,"@type":113},"Loss of Bap1 activates cDC1-CD8+ T cell-dependent antitumor immunity and creates an inflamed tumor microenvironment, with increased cDC1 and effector CD8+ T cells and decreased neutrophils and regulatory T cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337268,1790933120,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Cellular Oncology (2025) 48:183–203  \n[https://doi.org/10.1007/s13402-024-00978-y](https://doi.org/10.1007/s13402-024-00978-y)  \nRESEARCH  \nLoss of histone deubiquitinase Bap1 triggers anti-tumor immunity  \nHong Chang1 · Mingxia Li1 · Linlin Zhang1 · Meng Li4 · Swee Hoe Ong4 · Zhiwei Zhang1 · Jie Zheng1 · Xiang Xu1 · Yu Zhang1 · Jing Wang1 · Xingjie Liu1 · Kairui Li1 · Yao Luo1 · Haiyun Wang1 · Zhichao Miao5,6 · Xi Chen7 · Jie Zha2,3 · Yong Yu1  \nAccepted: 26 July 2024 / Published online: 14 August 2024 © The Author(s) 2024  \nAbstract  \nPurpose Immunotherapy using PD-L1 blockade is effective in only a small group of cancer patients, and resistance is common. This emphasizes the importance of understanding the mechanisms of cancer immune evasion and resistance.  \nMethods A genome-scale CRISPR-Cas9 screen identified Bap1 as a regulator of PD-L1 expression. To measure tumor size and survival, tumor cells were subcutaneously injected into both syngeneic WT mice and immunocompromised mice. The phenotypic and transcriptional characteristics of Bap1-deleted tumors were examined using flow cytometry, RNA-seq, and CUT&Tag-seq analysis.  \nResults We found that loss of histone deubiquitinase Bap1 in cancer cells activates a cDC1-CD8+ T cell-dependent antitumor immunity. The absence of Bap1 leads to an increase in genes associated with anti-tumor immune response and a decrease in genes related to immune evasion. As a result, the tumor microenvironment becomes inflamed, with more cDC1 cells and effector CD8+ T cells, but fewer neutrophils and regulatory T cells. We also found that the elimination of Bap1-deleted tumors depends on the tumor MHCI molecule and Fas-mediated CD8+ T cell cytotoxicity. Our analysis of TCGA data further supports these findings, showing a reverse correlation between BAP1 expression and mRNA signatures ofactivated DCs and T-cell cytotoxicity in various human cancers.  \nConclusion The histone deubiquitinase Bap1 could be used as a biomarker for tumor stratification and as a potential therapeutic target for cancer immunotherapies.  \nKeywords Bap1 · Tumor microenvironment · PD-L1 · Anti-tumor immunity  \nHong Chang and Mingxia Li have contributed equally.  \n􀀍 Jie Zha [zhajie@xmu.edu.cn](zhajie@xmu.edu.cn)  \n􀀍 Yong Yu [yy3@tongji.edu.cn](yy3@tongji.edu.cn)  \n1 Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, 1239 Siping Road, Shanghai 200092, China  \n2 Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, School of Medicine, Xiamen University, Xiamen, China  \n3 Key Laboratory of Xiamen for Diagnosis and Treatment of Hematological Malignancy, Xiamen, China  \n4 Wellcome Sanger Institute, Hinxton, Cambridge CB10 1HH, UK  \n5 Translational Research Institute of Brain and Brain-Like Intelligence, Department of Anesthesiology, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai 200081, China  \n6 GMU-GIBH Joint School of Life Sciences, The GuangdongHong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Laboratory, Guangzhou Medical University, Guangzhou, China  \n7 Department of Biology, Southern University of Science and Technology, 1088 Xueyuan Avenue, Shenzhen  \n518055, China  \n1 Introduction  \nWhile immunotherapy targeting PD-L1-mediated tumor tolerance has achieved remarkable clinical success in various cancers, it has only exhibited durable responses ina subset of patients [1, 2] . This suggests that a deeper and broader understanding of cancer immunity is necessary. The low response rates and durations of PD-L1 blockade agents can be attributed to two reasons: firstly, the mechanisms regulating PD-L1 expression for immune evasion indifferent cancer contexts are not completely understood. Secondly, there are tumor immune evasion mechanisms that are independent of PD-L1 .  \nRecent evidence supports the not","cbCaivpcJsg2zae6","https://ap.wps.com/l/cbCaivpcJsg2zae6","pdf",6769102,21,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Materials and methods\n## Mice","[{\"question\":\"Why is PD-L1 blockade immunotherapy limited in many cancer patients?\",\"answer\":\"PD-L1 blockade shows durable responses only in a small subset of patients, and resistance is common. The work emphasizes that immune evasion mechanisms regulating PD-L1 and mechanisms independent of PD-L1 contribute to low response rates.\"},{\"question\":\"How was Bap1 identified as relevant to PD-L1 regulation?\",\"answer\":\"A genome-scale CRISPR-Cas9 screen was used to identify Bap1 as a regulator of PD-L1 expression.\"},{\"question\":\"What immune effects result from loss of Bap1 in tumors?\",\"answer\":\"Loss of Bap1 activates cDC1-CD8+ T cell-dependent antitumor immunity and creates an inflamed tumor microenvironment, with increased cDC1 and effector CD8+ T cells and decreased neutrophils and regulatory T cells.\"}]","Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity - Research article summary | PDF",1790018426,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de622f035687782aba0fa8c92d800ff9.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7491065549b3fa62ab10793267d1a21f.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/539908cf93341edf057a43e00eb722ab.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c7515f9e18d22c600d71ebd527b1752.webp",980,1301]